News >

Entinostat/Exemestane Combo Misses OS Endpoint in HR+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, May 22, 2020

Briggs W. Morrison, MD, chief executive officer of Syndax

Briggs W. Morrison, MD

The combination of entinostat and exemestane did not show a statistically significant improvement in overall survival (OS) compared with exemestane alone in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer who have progressed on a nonsteroidal aromatase inhibitor, missing the primary endpoint of the phase 3 E2112 trial (NCT02115282).1

"We remain focused on advancing our broader portfolio, including our targeted therapy, SNDX-5613, an inhibitor of the Menin-MLL interaction, and axatilimab, our anti-CSF-1R monoclonal antibody,” Morrison added in the press release. “Later this year, we expect to present additional clinical data from the AUGMENT-101 trial of SNDX-5613 in adults with relapsed/refractory acute leukemias.”


  1. ECOG-ACRIN Provides Syndax Pharmaceuticals with results of phase 3 E2112 trial of entinostat plus exemestane in patients with HR+, HER2- breast cancer [news release]: Waltham, MA. Syndax Pharmaceuticals, Inc. Published May 21, 2020. Accesed May 22, 2020.
  2. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase ii, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17)2128-2135. doi:10.1200/JCO.2012.43.7251

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication